Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Malignant Tumor of Pancreas Metastatic to Liver 1Locally Advanced Unresectable Gastric Adenocarcinoma 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Radiosurgery 10Temozolomide 6Magnetic Resonance Spectroscopy 6pembrolizumab 3Trastuzumab 3Radiation 3fluciclovine F-18 2cabazitaxel 2Surgical Procedures, Operative 2Specimen Handling 2Radiotherapy 2Magnetic Resonance Imaging 2Erlotinib Hydrochloride 2Carboplatin 2Bevacizumab 2Aminolevulinic Acid 2tucatinib 1thymoglobulin 1tepotinib 1temsirolimus 1sodium thiosulfate 1ribociclib 1pazopanib 1patritumab deruxtecan 1palbociclib 1osimertinib 1neratinib 1lenvatinib 1irinotecan sucrosofate 1gancotamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Brain Neoplasms × irinotecan sucrosofate × Clear all
NCT05255666 2023-07-11

Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

Washington University School of Medicine

Phase 2 Withdrawn
BreastCNS

Brain Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡